[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "President Trump's medications in detail", "description": "Current infections\nUK\nCases, + 20, 641\nActive, 264,034\n\nUS\n\nCases, + 301,438 (last 7 days)\n\nPresident Trump\u2019s meds\n\nDr. Sean Conley\n\nOxygen dropped twice\n\nDid not need oxygen for long at all\n\nSlight cough\n\nViral load not established yet\n\nFever\n\nNow\n\nNo fever, reducing meds for past 72 hours\n\nNo evidence of live virus\n\nNormally 10 days after day 1\n\nMost viral shedding in first 5 days\n\nNot out of the woods yet\n\nhttps://www.bostonglobe.com/2020/10/05/nation/look-three-medications-president-trump-is-taking-treat-covid-19-what-they-do/\n\nRemdesivir\n\nRegeneron treatment, REGEN-CoV-2\n\nDexamethasone\n\nZinc\n\nVitamin D\n\nFamotidine\n\nMelatonin\n\nDaily aspirin\n\nRemdesivir\n\n5 days, intravenous\n\nFDA emergency approval for anyone in hospital with COVID\n\nProbably needs to be given very early\n\nEffect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19, A Randomized Clinical Trial, (JAMA, 21st August)\n\nhttps://jamanetwork.com/journals/jama/fullarticle/2769871\n\nn = 584\n\nModerate COVID-19\n\nRemdesivir group and standard care group\n\n7-point ordinal scale on study day 11\n\n5 day course, statistically significant difference in clinical status\n\nDifference was of uncertain clinical importance\n\n10 day course, no statistical difference from standard care\n\n\nAntibody therapy (Friday 2nd October, morning)\n\nMABs are produced from cell cultures\n\nREGEN-CoV-2\n\n8 grams\n\n2 antibodies which attach to the spike protein\n\n2 monoclonal antibodies\n\nOnly available for trial use\n\nGiven as compassionate use\n\nPassive immunity\n\nProbably lasts for 4 to 6 weeks\n\nRecovery trial\n\nhttps://www.recoverytrial.net\n\nRECOVERY COVID-19 phase 3 trial to evaluate Regeneron\u2019s REGN-COV2 investigational antibody cocktail in the UK\n\nhttps://www.recoverytrial.net/news/recovery-covid-19-phase-3-trial-to-evaluate-regeneron2019s-regn-cov2-investigational-antibody-cocktail-in-the-uk\n\n14th September\n\n2,000 patients in each group\n\nDexamethasone\n\nRecovery trial\n\nEarly use may reduce immune response\n\nDexamethasone in Hospitalized Patients with Covid-19 \u2014 Preliminary Report, (NEJM, 17th July\n\nhttps://www.nejm.org/doi/10.1056/NEJMoa2021436\n\nExperimental group, n = 2,104\n\nStandard care group, n = 4,321\n\nIn patients hospitalized with Covid-19,\n\nDexamethasone reduced 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone\n\nNo benefit in those receiving no respiratory support.\n\nGreatest benefit in those being ventilated\n\nZinc\n\nThe Role of Zinc in Antiviral Immunity, (Advances in Nutrition, July 2019)\n\nhttps://academic.oup.com/advances/article/10/4/696/5476413\n\nHundreds of key enzymes\n\nTranscription factor\n\nSecond-most abundant trace metal in the body\n\nZinc deficiency results in a compromised immune system\n\nRequired to mount an effective antiviral response\n\nDirect antiviral properties (e.g. influenza)\n\nCritical in generating innate and acquired antiviral responses\n\nThe Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis (Frontiers in Immunology, July, 2020)\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365891/\n\nPreserve natural tissue barriers\n\nRespiratory epithelium, preventing pathogen entry\n\nProbably useful, especially in zinc deficiency\n\nStudies are needed\n\nTesting the effect of zinc as therapeutic option for established disease\n\nCost-efficient\n\nGlobally available\n\nSimple to use\n\nLittle to no side effects\n\n\nVitamin D\n\nSpanish clinical trial\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456194/\n\nCalcifediol group, 2% required admission to the ICU\n\nControl group 50% admitted to ICU\n\nFamotidine\n\nH2-receptor antagonists\n\nCimetidine, ranitidine \n\nMelatonin\n\nHormone \n\nPineal gland\n\nRegulates the sleep\u2013wake cycle\n\nInteracts with the immune system\n\nReduces inflammation\n\nSafety and Efficacy of Melatonin in Outpatients Infected With COVID-19\nhttps://clinicaltrials.gov/ct2/show/NCT04474483\n\nPhase 2\n\n\nDaily aspirin\n300 mg\n600 mg\n900 mg\n\nLow dose\n\nhttps://www.nhs.uk/medicines/low-dose-aspirin/\n\n75 mg day\n\nStatins\nTalk to Karen about art books like the one she sent me\nhttps://www.youtube.com/redirect?redir_token=QUFFLUhqa1dFejhrQ2lJT2szOWJ0elJtR1JBaVZFQktRd3xBQ3Jtc0trVnUzMnFmQkhMdUt6WTlCRGtoNzg4MmpPOFZvSHRlR0xiclpicllUYU9OR1hoTmlES3lNWGVPQnZkdHBDR0gwanIxdXlYcWQ5UzZHWm1acHNITTY3Z2MzNnlFWVdaY0RqZHFnanEtcUVYQWFtUXc0TQ%3D%3D&q=http%3A%2F%2Fwww.spellboundbookart.co.uk%2F&stzid=UgxMhgA9qvEVlTtzD1p4AaABAg.9ET35P3BlFY9ET8tC1HdZH&event=comments", "link": "https://www.youtube.com/watch?v=zjfCccnmTb4", "date_published": "2020-10-05 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]